Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd ...
Zacks.com on MSN6d
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook
Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...
US FDA approves Evolus' two new anti-wrinkle gels
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.
Evolus’ (EOLS) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $27.00 price ...
Evolus announces FDA approval of Evolysse products
Evolus (EOLS) announced that the Food and Drug Administration has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, ...
Evolus Gets FDA Approval for Two Injectable Hyaluronic Acid Gels
Evolus said the Food and Drug Administration approved its injectable hyaluronic acid gels, known as Evolysse Form and Evolysse Smooth, in line with management expectations.
Evolus trading halted, news pending
EST Evolus (EOLS) trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...